U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal nerve U.S. launch supported by a waitlist of more than 1,500 patients, caregivers, and providers Visit www.monarch-etns.com for additional information on how to obtain the Gen 2 Monarch® device LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Lo

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts University in 2025 Foxcroft will conduct its first large mammal (canine) trial in mid-2026, using Hopewell’s LNPs WOBURN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Hopewell Therapeutics, Inc. , a Boston-based next-generation lipid nanoparticle (LNP) company (“ Hope

Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March 2026 LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch exte